Here, we found that HBV suppressed sorafenib-induced ferroptosis in HCC cells through the SRSF2/PCLAF tv1 pathway by lowering intracellular Fe2+ levels and boosting GPX4 expression. The gene discussed is SRSF2; the disease is hepatocellular carcinoma.